14:00 CET

Oncopeptides Virtual Capital Markets Day

The Program

14.00 – 16.00 CET (8:00am-10am EST) November 30th, 2020

 

“Building a Fully Integrated Biotechnology Company”

  • Introduction and Strategy for Value Growth – Marty J Duvall, CEO Oncopeptides
  • Multiple Myeloma
    “Myeloma remains one of the largest unmet medical needs within hematology”
    o Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York
  • Relapsed refractory multiple myeloma and melflufen – clinical experience with melflufen – Panel discussion
    o Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston
    o Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca
    Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides
  • The clinical development program for melflufen
    “Understanding how melflufen can help patients the most” – Jakob Lindberg, CSO Oncopeptides
  • Successfully making the drug available for patients in the US
    Overview of US launch of melflufen – Marty J Duvall, CEO Oncopeptides
  • Questions and Answers

 

The CMD will be webcasted live on the link:https://tv.streamfabriken.com/oncopeptides-cmd-2020

Upcoming events

European Myeloma Network Meeting 2021

-

Virtual meeting postponed to 3-6 March, 2021. The EMN meeting will be held in the virtual modality, on 3-6 March 2021.

Carnegie Healthcare Conference

-

47th Annual Meeting of the EBMT

-

The European Society for Blood and Marrow Transplantation 2021.

AACR Annual Meeting 2021

-

Virtual Meeting Week 1: April 10-15; Week 2: May 17-21

European School of Haematology E-conference 2021

-

E-Conference - How to Diagnose and Treat Multiple Myeloma.

COMy 2021

-

World Congress on Controversies in Multiple Myeloma 2021.

ASCO 2021 Annual Meeting

-

American Society of Clinical Oncology (ASCO) 2021.

EHA 2021 Virtual Congress

-

European Hematology Association Annual meeting 2021.

Interim Report Q2 2021

08:00 CET

Interim Report Q3 2021

08:00 CET